Atlas Trials

Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases

Clinical trial NCT07322718 · RECRUITING

Trial details

NCT number
NCT07322718
Sponsor
Ruijin Hospital
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Start date
2025-12-24
Primary completion
2027-12-19
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.